OncoMatch/Clinical Trials/NCT06776952
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Is NCT06776952 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for relapsed/refractory peripheral t cell lymphoma.
This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: CD30 positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: asparaginase/protease-containing regimen — for NK/T-cell lymphoma
subjects with NK/T-cell lymphoma require treatment with a regimen containing asparaginase/protease
Must have received: Brentuximab vedotin (Brentuximab vedotin) — for CD30 positive ALCL
subjects with CD30 positive ALCL require prior treatment with Brentuximab vedotin
Cannot have received: EZH2 inhibitor
Prior exposure to EZH2 inhibitor(s) or EZH1/2 inhibitor(s)
Cannot have received: HDAC inhibitor
Prior exposure to HDAC inhibitor(s)
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Have adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06776952 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EZH2 inhibitor, HDAC inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 0 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages